Novem Group’s Bristol-Myers Squibb BMY Stock Holding History

Novem Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.69M	Buy	64,002 +55,701	+671%	+$3.2M	0.37%	65
2026 Q1	$503K	Buy	8,301 +1,899	+30%	+$111K	0.06%	270
2025 Q4	$345K	Buy	6,402 +183	+3%	+$8.8K	0.04%	313
2025 Q3	$280K	Buy	+6,219	New	+$290K	0.03%	350
2025 Q2	–	Sell	-3,743	Closed	-$228K	–	408
2025 Q1	$228K	Buy	3,743 +117	+3%	+$6.82K	0.03%	326
2024 Q4	$205K	Buy	+3,626	New	+$203K	0.03%	346

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Novem Group's BMY Position: Q2 2026 in Review

Novem Group increased its Bristol-Myers Squibb (BMY) stake by 671% in Q2 2026, buying an estimated $3.2M and bringing the position to 64,002 shares worth $3.69M. The position accounts for 0.37% of the portfolio, ranked #65.

Novem Group first reported a position in BMY in Q4 2024 and has held it in 6 quarters since. 888 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Novem Group held 64,002 shares of Bristol-Myers Squibb worth $3.69M as of Q2 2026.
Novem Group bought 55,701 Bristol-Myers Squibb shares in Q2 2026, an estimated $3.2M.
Bristol-Myers Squibb made up 0.37% of Novem Group's portfolio in Q2 2026, its #65 holding.
Novem Group first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 6 quarters since.
888 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Novem Group's 13F filing for Q2 2026, filed 21 Jul 2026.